Overview

Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of TNP-2092 Capsules in Liver Cirrhosis Patients With Hyperammonemia

Status:
Completed

Trial end date:
2021-06-12

Target enrollment:

Participant gender:

Summary

The aim of this study was to evaluate the safety, tolerability, and pharmacokinetic characteristics of TNP-2092 Capsules in liver cirrhosis patients with hyperammonemia; and to preliminarily observe the effects of the study drug on blood ammonia and hepatic encephalopathy related clinical symptoms and signs, neuropsychological indicators, and quality of life in liver cirrhosis patients with hyperammonemia.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

TenNor Therapeutics (Suzhou) Limited

Treatments:

Rifamycins